Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ruggieri, S; Prosperini, L; Al-Araji, S; Annovazzi, PO; Bisecco, A; Ciccarelli, O; De, Stefano, N; Filippi, M; Fleischer, V; Evangelou, N; Enzinger, C; Gallo, A; Garjani, A; Groppa, S; Haggiag, S; Khalil, M; Lucchini, M; Mirabella, M; Montalban, X; Pozzilli, C; Preziosa, P; Río, J; Rocca, MA; Rovira, A; Stromillo, ML; Zaffaroni, M; Tortorella, C; Gasperini, C, , MAGNIMS, Study, Group.
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
J Neurol Neurosurg Psychiatry. 2023;
Doi: 10.1136/jnnp-2023-331920
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Enzinger Christian
- Khalil Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The assessment of treatment response is a crucial step for patients with relapsing-remitting multiple sclerosis on disease-modifying therapies (DMTs). We explored whether a scoring system developed within the MAGNIMS (MRI in Multiple Sclerosis) network to evaluate treatment response to injectable drugs can be adopted also to oral DMTs. METHODS: A multicentre dataset of 1200 patients who started three oral DMTs (fingolimod, teriflunomide and dimethyl fumarate) was collected within the MAGNIMS network. Disease activity after the first year was classified by the 'MAGNIMS' score based on the combination of relapses (0-≥2) and/or new T2 lesions (<3 or ≥3) on brain MRI. We explored the association of this score with the following 3-year outcomes: (1) confirmed disability worsening (CDW); (2) treatment failure (TFL); (3) relapse count between years 1 and 3. The additional value of contrast-enhancing lesions (CELs) and lesion location was explored. RESULTS: At 3 years, 160 patients experienced CDW: 12% of them scored '0' (reference), 18% scored '1' (HR=1.82, 95% CI 1.20 to 2.76, p=0.005) and 37% scored '2' (HR=2.74, 95% CI 1.41 to 5.36, p=0.003) at 1 year. The analysis of other outcomes provided similar findings. Considering the location of new T2 lesions (supratentorial vs infratentorial/spinal cord) and the presence of CELs improved the prediction of CDW and TFL, respectively, in patients with minimal MRI activity alone (one or two new T2 lesions). CONCLUSIONS: Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs.
- Find related publications in this database (Keywords)
- MRI
- MULTIPLE SCLEROSIS
- CLINICAL NEUROLOGY